Daily Endocrinology Research Analysis

BACKGROUND AND OBJECTIVE: To evaluate the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and intestinal cancers and to explore the risk factors for these associations. METHODS: PubMed, Embase, Web of Science, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched through 13 June 2024, to identify randomised clinical trials (RCTs) assessing the relationship between GLP-1 RA use and colorectal, colon, rectal, and intestinal cancers. Pooled relative risks (RRs) and 95% confidence intervals (CIs) for each outcome were calculated. RESULTS: In 17 RCTs comprising 36,415 patients, GLP-1 RAs was associated with a significantly reduced risk of colon cancer (RR, 0.34; 95% CI, 0.17-0.68; I

BACKGROUND: The latest updated 2025 and 2017 American College of Cardiology and the American Heart Association guidelines lowered the diagnostic threshold for hypertension to 130/80 mm Hg. Whether the new classification for hypertension has implications for reproductive outcomes remains uncertain. METHODS: This retrospective cohort study was conducted at the Reproductive Medicine Center of Shandong University in China. Women who underwent the initial embryo transfer of their first in vitro fertilization cycle were categorized into the normal blood pressure (BP), elevated BP, stage 1 hypertension, and stage 2 hypertension groups based on BP levels measured just before in vitro fertilization treatment. We examined associations of prepregnancy BP and reproductive outcomes. RESULTS: This study included 43 629 women who received in vitro fertilization treatment. The rate of live birth was lower in women with stage 1 and stage 2 hypertensions (46.1% and 41.4%, respectively) compared with women with normal BP (49.2%), with the adjusted relative ratios of 0.97 (95% CI, 0.937-0.996; CONCLUSIONS: Compared with normal BP, prepregnancy stage 1 and stage 2 hypertension were associated with a lower rate of live birth after in vitro fertilization treatment and increased risks of pregnancy complications.

CONTEXT: Multiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH). OBJECTIVE: In type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, metabolic syndrome) remains unclear. METHODS: We recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LFC) (LiverMultiScan): a) without steatosis; b) steatosis only without MASH; c) mild-moderate MASH (cT1 ≥800 to ≤875 ms); and d) severe MASH (cT1 >875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several non-invasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, MRE). RESULTS: Higher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all p<0.01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+® and CK-18) and more severe steatosis and fibrosis (all p<0.001). CONCLUSIONS: In people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.